These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27852142)

  • 21. CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation.
    Jain P; Burger JA; Khoury JD
    Am J Hematol; 2017 Oct; 92(10):1113-1114. PubMed ID: 28670739
    [No Abstract]   [Full Text] [Related]  

  • 22. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Richter's transformation of chronic lymphocytic leukemia with Hodgkin's-like cells is associated with Epstein-Barr virus infection.
    Rubin D; Hudnall SD; Aisenberg A; Jacobson JO; Harris NL
    Mod Pathol; 1994 Jan; 7(1):91-8. PubMed ID: 8159658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT.
    Bruzzi JF; Macapinlac H; Tsimberidou AM; Truong MT; Keating MJ; Marom EM; Munden RF
    J Nucl Med; 2006 Aug; 47(8):1267-73. PubMed ID: 16883004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
    Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
    Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Wąsik-Szczepanek E; Szymczyk A; Szczepanek D; Wszoła-Kleinrok J; Chocholska S; Pluta A; Hus M
    Adv Clin Exp Med; 2018 Dec; 27(12):1683-1689. PubMed ID: 30156387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Epstein-Barr virus associated Richter's syndrome accompanied by interstitial pneumonia].
    Otsuka E; Miyazaki Y; Moriyama K; Uno N; Kashima K; Nakayama T; Saburi Y; Kikuchi H; Nasu M
    Rinsho Ketsueki; 1999 May; 40(5):402-7. PubMed ID: 10390889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus in Burkitt's lymphoma: the missing link.
    Stebbing J; Bower M
    Lancet Oncol; 2009 Apr; 10(4):430. PubMed ID: 19341975
    [No Abstract]   [Full Text] [Related]  

  • 29. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
    Lee CS; Rattu MA; Kim SS
    J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab.
    van de Langerijt B; Doorduijn JK; Lam KH; van den Bent MJ
    J Neurol; 2011 May; 258(5):944-5. PubMed ID: 21136270
    [No Abstract]   [Full Text] [Related]  

  • 32. The use of ibrutinib in chronic lymphocytic leukemia.
    Damon LE
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
    [No Abstract]   [Full Text] [Related]  

  • 33. Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
    Raastad K; Huang Q
    Blood; 2021 Feb; 137(5):718. PubMed ID: 33538805
    [No Abstract]   [Full Text] [Related]  

  • 34. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Goldschmidt N; Rund D
    Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
    [No Abstract]   [Full Text] [Related]  

  • 35. Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
    Papageorgiou SG; Tsiodras S; Siakallis G; Bazani E; Spathis A; Poulakou G; Korkolopoulou P; Panayiotides I; Pappa V
    Pathol Res Pract; 2016 Dec; 212(12):1194-1198. PubMed ID: 28340951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
    Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
    Christoforidou A; Kapsas G; Bezirgiannidou Z; Papamichos S; Kotsianidis Ι
    Turk J Haematol; 2018 May; 35(2):147-149. PubMed ID: 29391330
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical and demographic characteristics of Epstein-Barr virus-associated childhood Burkitt's lymphoma in Southeastern Brazil: epidemiological insights from an intermediate risk region.
    Hassan R; Klumb CE; Felisbino FE; Guiretti DM; White LR; Stefanoff CG; Barros MH; Seuánez HN; Zalcberg IR
    Haematologica; 2008 May; 93(5):780-3. PubMed ID: 18367488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
    Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.